About Bio-Path
Paving the way for revolutionary treatment of disease
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in previously untreated AML patients, who are not eligible for or who have decided to forego intensive chemotherapy because of their fragile health, and in refractory/relapsed AML patients. Additionally, BP1001-A is being assessed in a Phase 1 study in refractory/relapsed patients with solid tumors. The Company’s second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in patients with refractory/relapsed lymphoma and AML.
A Gentler Path
AML incidence increases with age, with more than 50% of the cases in people age 60 or older. Prognosis for elderly AML patients remains very poor. The cure rate is between 5-15% in older adults, and those who cannot receive the standard course of high dose chemotherapy have an average survival rate of five to ten months. This is clearly a disease with a high unmet medical need. Prexigebersen, Bio-Path’s AML drug candidate, blocks the production of Grb2, a protein that is essential in regulating the proliferation and chemosensitivity of cancer cells. Inactivation of Grb2 has been shown to halt cancer cell proliferation and enhance the anticancer activity of chemotherapeutic agents.
Non-Hodgkin’s lymphoma (NHL) can start anywhere in the body where lymph tissue is found. Approximately 60% of NHLs are aggressive lymphomas that need to be treated right away, as they can grow and spread quickly to other parts of the lymph system or to other parts of the body. BP1002, our second drug candidate, targets the Bcl-2 protein, which is responsible for driving cancer cell survival. BP1002 is intended to target refractory/relapsed lymphoma, chronic lymphocytic leukemia, and AML. Inhibition of Bcl-2 has been shown to enhance the anticancer activity of chemotherapeutic agents and cancer cell death.
The Heart of Pittsburgh
Bio-Path is strategically headquartered in Pittsburgh, a city that has redefined itself as a global epicenter for the Innovation Boom. No longer defined by industry alone, today’s Pittsburgh is a high-tech fortress powered by world-class advancements in Artificial Intelligence, Robotics, and the Life Sciences.
A Foundation of Precision Technology
While Bio-Path was founded on foundational technology licensed from The University of Texas MD Anderson Cancer Center, the company has evolved into a powerhouse of original innovation. Our proprietary, patented tech stack—solely owned by the Company—represents a breakthrough in nanotechnology and precision medicine. Our intellectual property includes:
- Advanced Composition of Matter: Unique liposomal structures designed for stability.
- Systemic Delivery Methods: Patented processes for transporting antisense DNA targets through the vascular system.
- Smart Manufacturing: Proprietary protocols that bridge the gap between lab-scale discovery and clinical-grade production.
Leveraging the “Silicon Highland” Ecosystem
By operating within Pittsburgh’s dense academic and technical landscape, Bio-Path integrates with a network of premier clinical institutions and regional research centers. This “brain gain” environment allows us to collaborate with the same caliber of talent that has made Pittsburgh a leader in autonomous systems and biotech.
Bio-Path Holdings is aggressively scaling its pipeline for hematopoietic diseases and solid tumors, collaborating with the region’s clinical leaders to pioneer the next generation of therapeutic programs in and beyond oncology.
